CHICAGO, USA – AstraZeneca announced that its antibody-drug conjugate (ADC) therapy, Enhertu (trastuzumab deruxtecan), in combination with the monoclonal antibody pertuzumab, has achieved a breakthrough by reducing the risk of disease progression or death in early-stage breast cancer treatment by 44%. These results were demonstrated through the DESTINY-Breast09 Phase 3 clinical trial and were unveiled at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, drawing significant attention from healthcare professionals worldwide.

 
A Decade's Breakthrough: Great Hope for First-Line Treatment of HER2-Positive Breast Cancer

AstraZeneca emphasized that this study is the first clinical trial in the past decade to show improved outcomes for patients with HER2-positive metastatic breast cancer in the first-line setting. HER2-positive breast cancer accounts for 15-20% of all breast cancer cases and is characterized by aggressive cancer cells and rapid proliferation.

In this clinical trial, the progression-free survival (PFS) for the Enhertu and pertuzumab combination therapy group was 40.7 months, significantly longer than the 26.9 months observed in the standard treatment group, indicating prolonged survival without disease progression. Progression-free survival refers to the period from the start of treatment until the disease worsens or the patient dies, and it is a crucial indicator for evaluating the efficacy of new treatments.

 
Emphasizing the Importance of Early Treatment: Indicating Applicability to All HER2-Positive Metastatic Breast Cancer Patients

Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca, stated, "Treating at earlier stages of disease can make a bigger difference," adding that "if approved, Enhertu could be used for all HER2-positive metastatic breast cancer patients." This is considered a significant advancement that could change the treatment paradigm. First-line therapy is the initial treatment for a disease, often including chemotherapy or radiation after surgery, but when used alone, it is currently recognized as the most effective treatment.

Galbraith added that while some side effects were observed with this combination therapy, no new safety concerns emerged.

Dave Fredrickson, Executive Vice President, Oncology Business Unit at AstraZeneca, emphasized that the DESTINY-Breast09 study reaffirmed the importance of antibody-drug conjugates (ADCs) and that applying these innovative therapies at an earlier stage of the disease is crucial for achieving the best outcomes. ADCs are gaining attention as next-generation anticancer drugs that precisely deliver drugs to specific cancer cell targets, minimizing side effects while maximizing therapeutic efficacy.

 
HER2-Positive Breast Cancer: Aggressive Yet Hopeful Treatment Prospects

HER2-positive metastatic breast cancer is an aggressive subtype, accounting for 15-20% of all breast cancers, where overexpression of the HER2 gene promotes cancer cell growth and spread. Patients with this type of breast cancer historically had an average survival period of about five years, but these new research results are expected to bring a significant change to this prognosis.

Dr. Sara Tolaney, Chief of Breast Oncology at Dana-Farber Cancer Institute, highlighted the importance of this study, stating, "It's incredibly impressive that patients were able to have control of their cancer for almost double the time." This offers new hope to HER2-positive breast cancer patients and is expected to lead to substantial changes in future treatment guidelines. This study is also anticipated to provide new options for patients who have not responded to or have developed resistance to existing treatments, contributing to addressing unmet needs in the field of breast cancer treatment.

[Copyright (c) Global Economic Times. All Rights Reserved.]